Trial Profile
A Multinational, Multicenter, Phase III, Randomized Open-label Trial of Pembrolizumab Versus Docetaxel in Previously Treated Subjects With Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 06 Jul 2023 Primary endpoint (PFS Per RECIST 1.1 as Assessed by BICR in Participants With PD-L1 Positive (TPS 1%) Tumors (All Participants) [ Time Frame: Up to approximately 36 months (through Final Analysis cut-off date of 09-Sep-2019) ]) has not been met according to Results published in the International Journal of Cancer.
- 06 Jul 2023 Primary endpoint (Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With PD-L1 Positive (TPS 50%) Tumors [ Time Frame: Up to approximately 36 months (through Final Analysis cut-off date of 09-Sep-2019) ]) has not been met according to Results published in the International Journal of Cancer.
- 06 Jul 2023 Primary endpoint (OS in Participants With PD-L1 Positive (TPS 1%) Tumors (All Participants) [ Time Frame: Up to approximately 36 months (through Final Analysis cut-off date of 09-Sep-2019) ] has not been met according to Results published in the International Journal of Cancer.